2. Academic Validation
  3. Cucurbitacin B alleviates DSS-induced ulcerative colitis by improving gut microbiota disorder in C57BL/6 mice

Cucurbitacin B alleviates DSS-induced ulcerative colitis by improving gut microbiota disorder in C57BL/6 mice

  • AMB Express. 2025 Jul 26;15(1):111. doi: 10.1186/s13568-025-01922-5.
Jichen Li # 1 2,  Xiaodi Shen # 3,  Xia Wu 1 2,  Fan Zhao 1 2,  Wenling Tang 4,  Minglan Wu 1 2,  Fang Hu 3,  Xingjiang Hu 5 6,  Fei Wang 7,  Qiao Zhang 8
Affiliations

Affiliations

  • 1 Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.
  • 2 Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China.
  • 3 Phase I Clinical Research Center, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, China.
  • 4 Office of National Drug Clinical Trail Institution, The Fifth Affiliated Hospital, Wenzhou Medical University, Lishui, 323000, People's Republic of China.
  • 5 Zhejiang Provincial Key Laboratory of Traditional Chinese Medicine for Clinical Evaluation and Translational Research, Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China. huxingjiang@zju.edu.cn.
  • 6 Zhejiang Provincial Key Laboratory for Drug Evaluation and Clinical Research, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, 310003, People's Republic of China. huxingjiang@zju.edu.cn.
  • 7 Phase I Clinical Research Center, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, China. feiwang@zju.edu.cn.
  • 8 Phase I Clinical Research Center, The First Affiliated Hospital of Zhejiang Chinese Medical University (Zhejiang Provincial Hospital of Traditional Chinese Medicine), Hangzhou, 310006, China. 1316056@zju.edu.cn.
  • # Contributed equally.
PMID: 40715887 DOI: 10.1186/s13568-025-01922-5
Abstract

Cucurbitacin B (CuB) is a triterpenoid compound derived from various medicinal Plants, demonstrating potential anti-inflammatory, antioxidant, and neuroprotective properties, as well as significant anti-tumor effects. However, its efficacy in treating ulcerative colitis (UC) remains unclear. To investigate the therapeutic potential of CuB, a dextran sulfate sodium (DSS)-induced UC model in mice was employed, along with gut microbiota analysis. The results revealed that CuB significantly alleviated clinical symptoms, improved colonic tissue damage, and suppressed pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 in colon tissues. Additionally, CuB was associated with changes in specific microbial populations, including the upregulation of Muribaculaceae, Rikenellaceae_RC9_gut_group, Muribaculum, and Bifidobacterium, and the downregulation of Desulfovibrionaceae, Helicobacter, Escherichia-Shigella, Streptococcus, Candidatus_Saccharimonas, and Clostridium, which may contribute to the recovery of colon injury. This study provides preliminary evidence supporting CuB's therapeutic potential in DSS-induced colitis by enhancing gut microbiota diversity. CuB shows promise as potential treatment for UC and Other conditions related to disruptions in intestinal flora homeostasis.

Keywords

Cucurbitacin B; Dextran sulfate sodium; Microbiota; Ulcerative colitis.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z